STOCKHOLM, December 16, 2025 /PRNewswire/ --Affibody AB ("Affibody") today announced that the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results